Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Athenex Inc (CE) | ATNXQ | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.0152 | 0.0152 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.0003 - 0.23 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.0152 | USD |
Athenex Inc (CE) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 131.68k | 8.66M | - | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Athenex (CE) News
Date | Time | Source | News Article |
---|---|---|---|
10/02/2023 | 06:42 | Edgar (US Regulatory) | Form 8-K - Current report |
8/17/2023 | 15:06 | Edgar (US Regulatory) | Form 8-K - Current report |
7/18/2023 | 08:03 | Edgar (US Regulatory) | Form 8-K - Current report |
7/10/2023 | 05:05 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATNXQ Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.138 | 0.23 | 0.0003 | 0.1387482 | 50,650 | -0.1228 | -88.99% |
3 Years | 0.138 | 0.23 | 0.0003 | 0.1387482 | 50,650 | -0.1228 | -88.99% |
5 Years | 0.138 | 0.23 | 0.0003 | 0.1387482 | 50,650 | -0.1228 | -88.99% |
Athenex (CE) Description
Athenex is a clinical stage biotechnology company focused on the development of autologous and allogeneic NKT cell therapies to treat cancers. The company's goal is to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes of cancer patients. |